Pharmacological actions of statins: A critical appraisal in the management of cancer

Pharmacological Reviews

Volumn 64, Issue 1, 2012, Pages 102-146

  Gazzerro, Patrizia ^a   Proto, Maria Chiara ^a   Gangemi, Giuseppina ^a   Malfitano, Anna Maria ^a   Ciaglia, Elena ^a   Pisanti, Simona ^a   Santoro, Antonietta ^a   Laezza, Chiara ^b   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ATORVASTATIN; CALCIUM ANTAGONIST; CD4 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; CERIVASTATIN; COUMARIN ANTICOAGULANT; CYTOCHROME P450; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOLIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEVINOLIN; PECTIN; PITAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL;

AGE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILE FLOW; BINDING COMPETITION; BONE DENSITY; BONE METABOLISM; BRAN; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOKINE RELEASE; DIFFUSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME INHIBITION; ETHNICITY; FIRST PASS EFFECT; FOOD DRUG INTERACTION; FOOD INTAKE; FRACTURE; GASTROINTESTINAL SYMPTOM; GENDER; HUMAN; HYDROLYSIS; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY DISEASE; LEUKOCYTE MIGRATION; LIVER CELL; LIVER DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAXIMUM PLASMA CONCENTRATION; METABOLISM; MYALGIA; MYOPATHY; NEOPLASM; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SMOOTH MUSCLE FIBER; STEREOCHEMISTRY; T LYMPHOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; URINE COLOR; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 83455163746     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.004994     Document Type: Review

References (543)

1. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, and Holt PR (1999a) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223-2229.
2. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, and Holt PR (1999b) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838-847.
3. Ahn KS, Sethi G, and Aggarwal BB (2008b) Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 75:907-913.
4. Ahn KS, Sethi G, Chaturvedi MM, and Aggarwal BB (2008a) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclasto-genesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 123:1733-1740.
5. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, and Libby P (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tis-sue factor in vivo and in vitro. Circulation 103:276-283.
6. Alberts AW (1988) Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62:10J-15J.
7. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, et al. (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957-3961.
8. Ali F, Zakkar M, Karu K, Lidington EA, Hamdulay SS, Boyle JJ, Zloh M, Bauer A, Haskard DO, Evans PC, et al. (2009a) Induction of the cytoprotective enzyme hemeoxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J Biol Chem 284:18882-18892.
9. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, and Warner TD (2009b) Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 29:706-711.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998-3007.
11. Alvarez E, Rodino-Janeiro BK, Ucieda-Somoza R, and González-Juanatey JR (2010) Pravastatin counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma membrane of human endothelial cells. J Cardiovasc Pharmacol 55:203-212.
12. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM, et al. (2007) Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38:3198-3204.
13. Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, Kawakami M, and Momo-mura S (2009) Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J 73:1523-1530.
14. Araújo FA, Rocha MA, Mendes JB, and Andrade SP (2010) Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed Pharmacother 64:29-34.
15. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, and Schafer H (2001) Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20:859-868.
16. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.
17. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, and Kirschmeier P (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457.
18. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rossig L, Spyridopoulos I, Zeiher AM, and Dimmeler S (2003) HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92:1049-1055.
19. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, and Birnbaum Y (2006) Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J 151:976.e1-e6.
20. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, and Gullestad L (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syn-dromes. Circulation 100:614-620.
21. Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, Humbert H, and Sunkara G (2007) Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 23:2913-2920.
22. Azie NE, Brater DC, Becker PA, Jones DR, and Hall SD (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64:369-377.
23. Bachmakov I, Glaeser H, Fromm MF, and Konig J (2008) Interaction of oral antidi-abetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57:1463-1469.
24. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681.
25. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278.
26. Bao XM, Wu CF, and Lu GP (2009) Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Acta Pharmacol Sin 30:1392-1398.
27. Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, El-Remessy AB, Caldwell RW, Marcus DM, and Caldwell RB (2009) HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50:4934-4940.
28. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, and Pols HA (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146-152.
29. Bell DS, Al Badarin F, and O'Keefe JH Jr (2011) Therapies for diabetic dyslipidae-mia. Diabetes Obes Metab 13:313-325.
30. Benet LZ, Cummins CL, and Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398.
31. Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P, and Scotlandi K (2001) Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7:1790-1797.
32. Bergbrede T, Chuky N, Schoebel S, Blankenfeldt W, Geyer M, Fuchs E, Goody RS, Barr F, and Alexandrov K (2009) Biophysical analysis of the interaction of Rab6a GTPase with its effector domains. J Biol Chem 284:2628-2635.
33. Berk BC (2008) Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. Circulation 117:1082-1089.
34. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
35. Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, DeKosky S, and Burke GL (2011) Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002.
36. Bifulco M (2005) Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci 77:1740-1749.
37. Bifulco M (2008) Therapeutic potential of statins in thyroid proliferative disease. Nat Clin Pract Endocrinol Metab 4:242-243.
38. Bifulco M, Laezza C, Stingo S, and Wolff J (2002) 2,3-Cyclic nucleotide 3-phosphodiesterase: a membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc Natl Acad Sci USA 99:1807-1812.
39. Bil J, Zapala L, Nowis D, Jakobisiak M, and Golab J (2010) Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 288:57-67.
40. Birnbaum G, Cree B, Altafullah I, Zinser M, and Reder AT (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71:1390-1395.
41. Bjarnason NH, Riis BJ, and Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380-384.
42. Blais L, Desgagné A, and LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368.
43. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, and Danesi R (2005) Fluvastatin synergistically enhances the antiproliferative effect of gem-citabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93:319-330.
44. Bologa R, Levine D, Parker T, Gordon B, Lanto A, Cheigh J, Stenzel K, and Rubin A (2009) Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. Clin Nephrol 72:437-441.
45. Bombeli T, Karsan A, Tait JF, and Harlan JM (1997) Apoptotic vascular endothelial cells become procoagulant. Blood 89:2429-2442.
46. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, and McClung MR (2007) Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 92:4671-4677.
47. Bonovas S, Filioussi K, Flordellis CS, and Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462-3468.
48. Bottorff M and Hansten P (2000) Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med 160:2273-2280.
49. Bourcier T and Libby P (2000) HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20:556-562.
50. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, and Tonn JC (2000) Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20:2761-2771.
51. Braatvedt GD, Bagg W, Gamble G, Davidson J, and Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766-770.
52. Braun PE, De Angelis D, Shtybel WW, and Bernier L (1991) Isoprenoid modification permits 2,3-cyclic nucleotide 3-phosphodiesterase to bind to membranes. J Neuro sci Res 30:540-544.
53. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, and Feron O (2001) Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89:866-873.
54. Bruner-Tran KL, Osteen KG, and Duleba AJ (2009) Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 94:2489-2494.
55. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, and Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63:5656-5668.
56. Budman DR, Tai J, and Calabro A (2007) Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 104:93-101.
57. Burtenshaw AJ, Sellors G, and Downing R (2008) Presumed interaction of fusidic acid with simvastatin. Anaesthesia 63:656-658.
58. Cafforio P, Dammacco F, Gernone A, and Silvestris F (2005) Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26:883-891.
59. Caine GJ, Stonelake PS, Lip GY, and Kehoe ST (2002) The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4:465-473.
60. Calabro A, Tai J, Allen SL, and Budman DR (2008) In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 19:705-712.
61. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, et al. (2005) Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 352:1667-1676.
62. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, and Chiodo F (2008) Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholester-olaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 6:572-578.
63. Camoretti-Mercado B (2009) Targeting the airway smooth muscle for asthma treatment. Transl Res 154:165-174.
64. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al. (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707-8714.
65. Canonico M, Plu-Bureau G, Lowe GD, and Scarabin PY (2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336:1227-1231.
66. Casey PJ and Seabra MC (1996) Protein prenyltransferases. J Biol Chem 271:5289-5292.
67. Catapano AL (2010) Pitavastatin-pharmacological profile from early phase studies. Atheroscler Suppl 11:3-7.
68. Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, and Crowell DN (1996) Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett 110:49-55.
69. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT, et al. (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98:700-707.
70. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, and Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749-756.
71. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, and Dimitroulakos J (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90:9-17.
72. Cerezo-Guisado MI, García-Román N, García-Marín LJ, Alvarez-Barrientos A, Bra-gado MJ, and Lorenzo MJ (2007) Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J 401: 175-183.
73. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, and Lerman LO (2006) Simva-statin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 20:1706-1708.
74. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, and Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188.
75. Chang CC, Ho SC, Chiu HF, and Yang CY (2011) Statins increase the risk of prostate cancer: A population-based case-control study. Prostate 71:1818-1824.
76. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, and Ridker PM (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827.
77. Chello M, Spadaccio C, Patti G, Lusini M, Barbato R, Goffredo C, Di Sciascio G, and Covino E (2008) Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis 197:588-595.
78. Chen CL, Huang SS, and Huang JS (2008) Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol 215:223-233.
79. Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, Amin RD, and Quan H (1992) Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 9:1629-1633.
80. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, et al. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-1256.
81. Chiba Y, Sato S, and Misawa M (2008) Inhibition of antigen-induced bronchial smooth muscle hyperresponsiveness by lovastatin in mice. J Smooth Muscle Res 44:123-128.
82. Chiu LM, Menhinick AM, Johnson PW, and Amsden GW (2002) Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 50:1075-1079.
83. Choi DH, Li C, and Choi JS (2009) Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 34:163-168.
84. Choi JS, Piao YJ, and Han HK (2006) Pharmacokinetic interaction between fluva-statin and diltiazem in rats. Biopharm Drug Dispos 27:437-441.
85. Chow SC (2009) Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 57:243-251.
86. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, Wattanasirichaigoon S, and Kaufman L (2010) Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46:1011-1015.
87. Chung YS, Lee MD, Lee SK, Kim HM, and Fitzpatrick LA (2000) HMG-CoA re-ductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endo-crinol Metab 85:1137-1142.
88. Cilla DD Jr, Gibson DM, Whitfield LR, and Sedman AJ (1996) Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholes-terolemic subjects in the morning and evening. J Clin Pharmacol 36:604-609.
89. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, and Davì G (2002) Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106:399-402.
90. Clunn GF, Sever PS, and Hughes AD (2010) Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int J Cardiol 139:2-6.
91. Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M, and Millar JL (1998) Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 102:522-527.
92. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised pla-cebo-controlled trial. Lancet 364:685-696.
93. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, and CARDS Investigators (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54:810-819.
94. Collins SP, Reoma JL, Gamm DM, and Uhler MD (2000) LKB1, a novel serine/ threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J 345: 673-680.
95. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, and Kolodney MS (2003) Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2:941-948.
96. Coogan PF, Rosenberg L, and Strom BL (2007a) Statin use and the risk of 10 cancers. Epidemiology 18:213-219.
97. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, and Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13:262-267.
98. Coogan PF, Smith J, and Rosenberg L (2007b) Statin use and risk of colorectal cancer. J Natl Cancer Inst 99:32-40.
99. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, and Cantarini MV (2003) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73:322-329.
100. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, and Landreth G (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280:34202-34209.
101. Cordle A and Landreth G (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 25:299-307.
102. Corriere MA, Edwards MS, Pearce JD, Andrews JS, Geary RL, and Hansen KJ (2009) Restenosis after renal artery angioplasty and stenting: incidence and risk factors. J Vasc Surg 50:813-819.e1.
103. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, and Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428.
104. Corsini A, Maggi FM, and Catapano AL (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31:9-27.
105. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, and Paoletti R (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101:117-125.
106. Cramer C, Haan MN, Galea S, Langa KM, and Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71:344-350.
107. Croizet-Berger K, Daumerie C, Couvreur M, Courtoy PJ, and van den Hove MF (2002) The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci USA 99:8277-8282.
108. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofe-nadine. Drug Metab Dispos 27:866-871.
109. Cziraky MJ, Watson KE, and Talbert RL (2008) Targeting low HDL cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14 (8 Suppl):S3-S28.
110. Daaka Y (2004) G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004:re2.
111. Dai YL, Luk TH, Siu CW, Yiu KH, Chan HT, Lee SW, Li SW, Tam S, Fong B, Lau CP, et al. (2010) Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease. Cardiovasc Toxicol 10:130-138.
112. Dain JG, Fu E, Gorski J, Nicoletti J, and Scallen TJ (1993) Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 21:567-572.
113. Dale KM, Coleman CI, Henyan NN, Kluger J, and White CM (2006) Statins and Cancer Risk. A Meta-analysis. JAMA 295:74-80.
114. Daub K, Lindemann S, Langer H, Seizer P, Stellos K, Siegel-Axel D, and Gawaz M (2007) The evil in atherosclerosis: adherent platelets induce foam cell formation. Semin Thromb Hemost 33:173-178.
115. Davì G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, and Patrono C (1992) Increased thromboxane biosynthesis in type IIa hypercho-lesterolemia. Circulation 85:1792-1798.
116. Davidson MH (2002) Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 11:125-141.
117. Deblois D, Tea BS, Beaudry D, and Hamet P (2005) Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. Can J Physiol Pharmacol 83:29-41.
118. DeClue JE, Vass WC, Papageorge AG, Lowy DR, and Willumsen BM (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712-717.
119. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, and Soria C (2003) Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 15: 327-338.
120. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganné F, Vannier JP, Soria J, and Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22:1139-1148.
121. Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, and Parr G (2010) Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 50: 1188-1201.
122. Desager JP and Horsmans Y (1996) Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clinical Pharmacokinetics 31: 348-371.
123. Deschaseaux F, Selmani Z, Falcoz PE, Mersin N, Meneveau N, Penfornis A, Klein-clauss C, Chocron S, Etievent JP, Tiberghien P, et al. (2007) Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors. Eur J Pharmacol 562:111-118.
124. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, and Penn LZ (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93:1308-1318.
125. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, and Penn LZ (2000) Lovastatin induces a pronounced differentiation response in acute myeloid leuke-mias. Leuk Lymphoma 40:167-178.
126. Dimitroulakos J and Yeger H (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 2:326-333.
127. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, and Zeiher AM (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391-397.
128. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, and Psaty BM (2004) HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2:700-701.
129. Donaldson KL, Goolsby GL, and Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847-855.
130. Dong J, Yu X, Wang L, Sun YB, Chen XJ, and Wang GJ (2008) Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Acta Pharmacol Sin 29:1247-1252.
131. Doppenschmitt S, Spahn-Langguth H, Regårdh CG, and Langguth P (1999) Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88:1067-1072.
132. Douketis JD, Melo M, Bell CM, and Mamdani MM (2007) Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med 120:369.e9-369.e14.
133. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, and Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622.
134. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
135. Doyon M, Hale TM, Huot-Marchand JE, Wu R, de Champlain J, and DeBlois D (2011) Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo? Vascul Pharmacol 54:5-12.
136. Duncan RE, El-Sohemy A, and Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14:1897-1898.
137. Duncan RE, El-Sohemy A, and Archer MC (2007) Statins and cancer. Epidemiology 18:520; author reply, 520-521.
138. Duggan DE and Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 22:333-362.
139. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, and Coxon FP (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42 and Rho GTPases. J Bone Miner Res 21:684-694.
140. Dupuis J, Tardif JC, Cernacek P, and Théroux P (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 99:3227-3233.
141. Edwards CJ, Hart DJ, and Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-2219.
142. Endo A, Kuroda M, and Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (To-kyo) 29:1346-1348.
143. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-8885.
144. Erl W (2005) Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord 5:135-144.
145. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, and Gaziano JM (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139.
146. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861.
147. Feleszko W, Bałkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, and Jakóbisiak M (1999) Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560-567.
148. Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A, and Jakóbisiak M (2002) Synergistic interaction between highly specific cyclooxygen-ase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 9:879-885.
149. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, and Jakóbisiak M (2000) Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6:2044-2052.
150. Feleszko W, Zagozdzon R, Gołab J, and Jakóbisiak M (1998) Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34:406-411.
151. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407.
152. Ferri N, Granata A, Pirola C, Torti F, Pfister PJ, Dorent R, and Corsini A (2008) Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 74:144-153.
153. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, and Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluva-statin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27:410-416.
154. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, And West of Scotland Coronary Prevention Study Group (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357:1477-1486.
155. Frick M, Dulak J, Cisowski J, Józkowicz A, Zwick R, Alber H, Dichtl W, Schwar-zacher SP, Pachinger O, and Weidinger F (2003) Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 170:229-236.
156. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, and Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27-36.
157. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, and Olsen JH (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643-647.
158. Fritz G, Brachetti C, and Kaina B (2003) Lovastatin causes sensitization of HeLa cells to ionizing radiationinduced apoptosis by the abrogation of G2 blockage. Int J Radiat Biol 79:601-610.
159. Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B, and Marie PJ (2011) CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 26:1533-1542.
160. Fujino H, Yamada I, Shimada S, Yoneda M, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyl-transferase enzymes involved in lactonization. Xenobiotica 33:27-41.
161. Fukuda D, Enomoto S, Shirakawa I, Nagai R, and Sata M (2009) Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol 612:87-92.
162. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker CF, Sklar P, et al. (2011) High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 203:756-764.
163. García MJ, Reinoso RF, Sánchez Navarro A, and Prous JR (2003) Clinical pharma-cokinetics of statins. Methods Find Exp Clin Pharmacol 25:457-481.
164. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, Klinghammer L, Daniel WG, and Schmeisser A (2001) Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86:649-655.
165. Garnett WR (1995) Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 52:1639-1645.
166. Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V, and Greenwood J (2005) Suppression of autoimmune retinal disease by lova-statin does not require Th2 cytokine induction. J Immunol 174:2327-2335.
167. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, and Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628.
168. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL, Pasini FL, and Baldari CT (2005) Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 19:605-607.
169. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, and Whitfield LR (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36:242-246.
170. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, and Hassoun PM (2007) Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 292:L1105-L1110.
171. Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, and Larsson O (2000) Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des 15:67-72.
172. Glomset JA, Gelb MH, and Farnsworth CC (1990) Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci 15:139-142.
173. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, and Ridker PM (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851-1861.
174. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, and Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388-2394.
175. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Wagger-shauser T, Helmberger T, Walter A, et al. (2008) Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78:34-38.
176. Grana TM, Rusyn EV, Zhou H, Sartor CI, and Cox AD (2002) Ras mediates radio-resistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated ki-nase kinase-independent signaling pathways. Cancer Res 62:4142-4150.
177. Greenwood J, Steinman L, and Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358-370.
178. Guruswamy S and Rao CV (2009) Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int J Oncol 35:1037-1043.
179. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, and Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80:13-17.
180. Hamelin BA and Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Phar-macol Sci 19:26-37.
181. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, and Imaizumi T (2007) Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 27:1471-1477.
182. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, and Sabe H (2004) Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA 101:6647-6652.
183. Hasselbalch HC and Riley CH (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 30:1217-1225.
184. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of phar-macokinetic events. Clin Pharmacokinet 39:397-412.
185. He H, Dai F, Yu L, She X, Zhao Y, Jiang J, Chen X, and Zhao S (2002) Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr 10:231-242.
186. He HT, Lellouch A, and Marguet D (2005) Lipid rafts and the initiation of T cell receptor signaling. Semin Immunol 17:23-33.
187. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22.
188. Heeba GH and Abd-Elghany MI (2010) Effect of combined administration of ginger (Zingiber officinale Roscoe) and atorvastatin on the liver of rats. Phytomedicine 17:1076-1081.
189. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, and CAPTURE Study Investigators (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104-1111.
190. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, and Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594.
191. Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen YX, Filion L, and O'Brien ER (2011) Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One 6:e16413.
192. Hickmott H, Wynne H, and Kamali F (2003) The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 89:949-950.
193. Hillyard DZ, Jardine AG, McDonald KJ, and Cameron AJ (2004) Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis 172:219-228.
194. Hindler K, Cleeland CS, Rivera E, and Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306-315.
195. Hippisley-Cox J and Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197.
196. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, et al. (1997) Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272:13-16.
197. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
198. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, and Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349:151-154.
199. Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, et al. (2006) Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 44:163-171.
200. Holstein SA and Hohl RJ (2001a) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141-149.
201. Holstein SA and Hohl RJ (2001b) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25:651-660.
202. Hong SP, Chang KS, Choi DH, and Choi JS (2007) Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Arch Pharm Res 30:90-95.
203. Hong SP, Chang KS, Koh YY, Choi DH, and Choi JS (2009) Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Arch Pharm Res 32:1447-1452.
204. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P, and Weber C (2007) Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Athero-sclerosis 192:413-420.
205. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
206. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, and Kerr BM (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrobial Agents And Chemotherapy 45:3445-3450.
207. Huether A, Hopfner M, Baradari V, Schuppan D, and Scherubl H (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70:1568-1578.
208. Hughes A, Rogers MJ, Idris AI, and Crockett JC (2007) A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 81:403-413.
209. Hui CK, Cheung BM, and Lau GK (2005) Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 59:291-297.
210. Hutchison CJ (2002) Lamins: building blocks or regulators of gene expression? Nat Rev Mol Cell Biol 3:848-858.
211. Ichimaru N, Takahara S, Moriyama T, Kondo M, Nonomura N, Tanaka T, Wang JD, Imai E, Okuyama A, and Kondo Y (2004) Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolaemic patients on maintenance haemodi-alysis. J Int Med Res 32:45-52.
212. Ifergan I, Wosik K, Cayrol R, Kébir H, Auger C, Bernard M, Bouthillier A, Moum-djian R, Duquette P, and Prat A (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 60:45-55.
213. Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H, Ogawa A, Miura A, Miura D, Oto T, et al. (2010) Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 55:39-48.
214. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, et al. (2002) Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 290:131-139.
215. Inoue T and Node K (2009) Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 73:615-621.
216. Is ̧eri S, Ercan F, Gedik N, Yuksel M, and Alican I (2007) Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 230:256-264.
217. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K, Suzuki M, Itohara S, Nakahata T, Hiai H, et al. (2003) Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4:55-65.
218. Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
219. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, and Christians U (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369-1378.
220. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140-1146.
221. Jacobson TA (2011) Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Int J Clin Pract 65:82-101.
222. Jarvisalo MJ, Toikka JO, Vasankari T, Mikkola J, Viikari JS, Hartiala JJ, and Raitakari OT (1999) HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 147:237-242.
223. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, and Wessely R (2005) Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 68:483-492.
224. Jasin ́ska M, Owczarek J, and Orszulak-Michalak D (2006) The influence of simva-statin at high dose and diltiazem on myocardium in rabbits, the biochemical study. Acta Pol Pharm 63:386-390.
225. Javanmoghadam-Kamrani S and Keyomarsi K (2008) Synchronization of the cell cycle using lovastatin. Cell Cycle 7:2434-2440.
226. Jialal I and Bajaj M (2009) Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol 20:85-86.
227. Jiang Z, Zheng X, Lytle RA, Higashikubo R, and Rich KM (2004) Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 89:168-178.
228. Jick H, Zornberg GL, Jick SS, Seshadri S, and Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627-1631.
229. Jin W, Wu L, Liang K, Liu B, Lu Y, and Fan Z (2003) Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89:185-191.
230. Josan K, Majumdar SR, and McAlister FA (2008) The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178:576-584.
231. Kaczmarek D, Hohlfeld T, Wambach G, and Schror K (1993) The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterol-aemia. A double-blind, placebo-controlled, prospective study. Eur J Clin Pharma-col 45:451-457.
232. Kahri AJ, Valkonen MM, Vuoristo MK, and Pentikainen PJ (2004) Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharma-cother 38:719.
233. Kaji H, Kanatani M, Sugimoto T, and Chihara K (2005) Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 37:589-592.
234. Kaji H, Naito J, Inoue Y, Sowa H, Sugimoto T, and Chihara K (2008) Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway. Horm Metab Res 40:746-751.
235. Kajinami K, Mabuchi H, and Saito Y (2000) NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 9:2653-2661.
236. Kalmijn S, Feskens EJ, Launer LJ, and Kromhout D (1996) Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27:2230-2235.
237. Kamm CP, Mattle HP, And SWABIMS Study Group (2009) SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)-rationale, design and methodology. Trials 10:115.
238. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, and Roy TM (2001) Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 94:339-341.
239. Kaneider NC, Egger P, Dunzendorfer S, and Wiedermann CJ (2002) Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 22:1029-1035.
240. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, et al. (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363:751-756.
241. Kantola T, Kivisto KT, and Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397-402.
242. Kantola T, Kivisto KT, and Neuvonen PJ (1999) Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54:851-855.
243. Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, Mar-ciante K, Heckbert SR, Psaty BM, and Totah RA (2010) Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 20:619-629.
244. Kassan M, Montero MJ, and Sevilla MA (2009) Chronic treatment with pravastatin prevents cardiovascular alterations produced at early hypertensive stage. Br J Pharmacol 158:541-547.
245. Kassan M, Montero MJ, and Sevilla MA (2010) In vitro antioxidant activity of pravastatin provides vascular protection. Eur J Pharmacol 630:107-111.
246. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, and Hatzitolios AI (2010) Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimen-tal? Atherosclerosis 211:9-14.
247. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, and Guillem JG (2005) Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62:1363-1370.
248. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, et al. (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84:886-891.
249. Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SC, and Eiger G (2010) Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 123:60-65.
250. Khosravi-Far R, Cox AD, Kato K, and Der CJ (1992) Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ 3:461-469.
251. Khurana V, Bejjanki HR, Caldito G, and Owens MW (2007) Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288.
252. Kim KH, Kang JY, Kim DH, Park SH, Park SH, Kim D, Park KD, Lee YJ, Jung HC, Pan JG, et al. (2011) Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants. Drug Metab Dispos 39:140-150.
253. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, and Kang WK (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81-83.
254. Kim Y, Park K, and Kang W (2010) Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. Biopharm Drug Dispos 31:443-449.
255. Kimura T, Kaneko Y, Yamada S, Ishihara H, Senda T, Iwamatsu A, and Niki I (2008) The GDP-dependent Rab27a effector coronin 3 controls endocytosis of secretory membrane in insulin-secreting cell lines. J Cell Sci 121:3092-3098.
256. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
257. Klomp M, Beijk MA, Tijssen JG, and de Winter RJ (2011) Significant intimal hyperplasia regression between 6 and 18 months following Genous™ endothelial progenitor cell capturing stent placement. Int J Cardiol 147:289-291.
258. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, and Oza AM (2005) A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 41:523-530.
259. Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, Hirano T, and Iseki K (2008) Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci 82:969-975.
260. Konig J, Cui Y, Nies AT, and Keppler D (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164.
261. Konstantinopoulos PA, Karamouzis MV, and Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6:541-555.
262. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, et al. (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin high-dose Ara-C: a phase 1 study. Blood 109:2999-3006.
263. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, and Cutler DL (2004) Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 20:1185-1195.
264. Koyuturk M, Ersoz M, and Altiok N (2007) Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250:220-228.
265. Kritchevsky SB and Kritchevsky D (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391-416.
266. Krystal GW, Sulanke G, and Litz J (2002) Inhibition of phosphatidylinositol 3-ki-nase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1:913-922.
267. Kuipers HF and van den Elsen PJ (2005a) Statins and control of MHC2TA gene transcription. Nat Med 11:365-366.
268. Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, and van den Elsen PJ (2005b) Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 66:653-665.
269. Kuipers HF, Rappert AA, Mommaas AM, van Haastert ES, van der Valk P, Boddeke HW, Biber KP, and van den Elsen PJ (2006) Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia 53:115-123.
270. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, and Esserman LJ (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17:1028-1033.
271. Kuoppala J, Lamminpaa A, and Pukkala E (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44:2122-2132.
272. Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, and Abe K (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371:161-170.
273. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010.
274. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, and Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61:4885-4891.
275. Kuwana M, Okazaki Y, and Kaburaki J (2009) Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 19:530-535.
276. Kwak B, Mulhaupt F, Myit S, and Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402.
277. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, et al. (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104.
278. LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, Black H, Curb JD, Greenland P, Woods NF, et al. (2008) Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 63:369-375.
279. Lacut K, Oger E, Le Gal G, Couturaud F, Louis S, Leroyer C, and Mottier D (2004) Statins but not fibrates are associated with a reduced risk of venous thromboem-bolism: a hospital-based case-control study. Fundam Clin Pharmacol 18:477-482.
280. Laezza C, Di Marzo V, and Bifulco M (1998) v-K-ras leads to preferential farnesy-lation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid path-way. Proc Natl Acad Sci USA 95:13646-13651.
281. Laezza C, Fiorentino L, Pisanti S, Gazzerro P, Caraglia M, Portella G, Vitale M, and Bifulco M (2008) Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J Mol Med 86:1341-1351.
282. Laezza C, Wolff J, and Bifulco M (1997) Identification of a 48-kDa prenylated protein that associates with microtubules as 2,3-cyclic nucleotide 3-phosphodiesterase in FRTL-5 cells. FEBS Lett 413:260-264.
283. Lamprecht J, Wójcik C, Jakóbisiak M, Stoehr M, Schrorter D, and Paweletz N (1999) Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int 23:51-60.
284. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neo-vascularization, left ventricular function, and survival after experimental myocar-dial infarction requires endothelial nitric oxide synthase. Circulation 110:1933-1939.
285. Larner J, Jane J, Laws E, Packer R, Myers C, and Shaffrey M (1998) A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21:579-583.
286. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435.
287. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, and Endres M (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31:2442-2449.
288. Laufs U, Marra D, Node K, and Liao JK (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274:21926-21931.
289. Launay-Vacher V, Izzedine H, and Deray G (2005) Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 101:9-17.
290. Le Goff-Klein N, Koffel JC, Jung L, and Ubeaud G (2003) In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice. Eur J Pharm Sci 18:31-35.
291. 2 and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol 15:759-764.
292. Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh do Y, Shin DB, Kim TW, Lee N, et al. (2009) Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOL-FIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 64:657-663.
293. Lee SJ, Qin H, and Benveniste EN (2008) The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 38:2325-2336.
294. Lee YM, Chen WF, Chou DS, Jayakumar T, Hou SY, Lee JJ, Hsiao G, and Sheu JR (2010) Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci 17:45.
295. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
296. Leone AM, Rutella S, Giannico MB, Perfetti M, Zaccone V, Brugaletta S, Garramone B, Niccoli G, Porto I, Liuzzo G, et al. (2008) Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol 130:457-462.
297. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, Nader M, and Schusdziarra V (2004) Treatment of HCC with pravastatin, octreotide, or gemcitabine-a critical evaluation. Hepatogastroenterology 51:1099-1103.
298. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524-1530.
299. Leung KF, Baron R, and Seabra MC (2006) Thematic review series: lipid posttrans-lational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 47:467-475.
300. Li J, Li JJ, He JG, Nan JL, Guo YL, and Xiong CM (2010) Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc Ther 28:8-14.
301. Li L, Cao D, Kim H, Lester R, and Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60:729-739.
302. Lilja JJ, Kivisto KT, and Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pha-rmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 68:384-390.
303. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, and Lameire NH (2003) Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 18:967-976.
304. LIPID Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357.
305. Lishner M, Bar-Sef A, Elis A, and Fabian I (2001) Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 49:319-324.
306. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, and Shi GP (2010) Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 48:798-802.
307. Liuni A, Luca MC, Gori T, and Parker JD (2010) Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cycloox- ygenase-2-dependent mechanism. J Am Coll Cardiol 55:1002-1006.
308. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, and Asahara T (2001) HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108:399-405.
309. Luisetto G and Camozzi V (2009) Statins, fracture risk, and bone remodeling. J Endocrinol Invest 32 (4 Suppl):32-37.
310. Ma FX, Chen F, Ren Q, and Han ZC (2009) Lovastatin restores the function of endothelial progenitor cells damaged by oxLDL. Acta Pharmacol Sin 30:545-552.
311. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, and Bokelman DL. (1988) Preclinical evaluation of lovastatin. Am J Cardiol 62:16J-27J.
312. Makabe S, Takahashi Y, Watanabe H, Murakami M, Ohba T, and Ito H (2010) Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis 213:377-384.
313. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, and Ghosh-Choudhury N (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antag-onistic interplay between p53 and CD44. J Biol Chem 286:11314-11327.
314. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, and Dimitroulakos J. (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11:2398-2407.
315. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, and Dimitroulakos J (2003) Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 129:631-641.
316. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, and Denner L (1998) Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83.
317. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-Garci ́a B, Vega M, Serrano J, Ortega L, Hernández G, Tuño ́n J, and Egido J (2005) Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and hu-man atherosclerotic lesions in one month. Stroke 36:1796-1800.
318. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, and Koenig W (2003) Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107:1954-1957.
319. McKay A, Leung BP, McInnes IB, Thomson NC, and Liew FY (2004) A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172:2903-2908.
320. Medina MW, Gao F, Ruan W, Rotter JI, and Krauss RM (2008) Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118:355-362.
321. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, Milani RV, and Lavie CJ (2002) Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40:1609-1614.
322. Mehta JL, Li DY, Chen HJ, Joseph J, and Romeo F (2001) Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 289: 857-861.
323. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, and Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210.
324. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, and Jick H (2001) Statins and fracture risk. JAMA 286:669-670.
325. Memon AR (2004) The role of ADP-ribosylation factor and SAR1 in vesicular traf-ficking in plants. Biochim Biophys Acta 1664:9-30.
326. Metzger BT, Barnes DM, and Reed JD (2009) A comparison of pectin, polyphenols, and phytosterols, alone or in combination, to lovastatin for reduction of serum lipids in familial hypercholesterolemic swine. J Med Food 12:854-860.
327. Miida T, Takahashi A, and Ikeuchi T (2007) Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther 113:378-393.
328. Minden MD, Dimitroulakos J, Nohynek D, and Penn LZ (2001) Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40:659-662.
329. Mitsios JV, Papathanasiou AI, Goudevenos JA, and Tselepis AD (2010) The anti-platelet and antithrombotic actions of statins. Curr Pharm Des 16:3808-3814.
330. Miyauchi K, Kasai T, Yokayama T, Aihara K, Kurata T, Kajimoto K, Okazaki S, Ishiyama H, and Daida H (2008) Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J 72:832-838.
331. Mobarrez F, Antovic J, Egberg N, Hansson M, Jorneskog G, Hultenby K, and Wallén H (2010) Amulticolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 125:e110-6.
332. Moghadasian MH. (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coen-zyme A reductase inhibitors. Life Sci 65:1329-1337.
333. Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, Wong WS, Tse HF, and Lau CS (2010) Low circulating level of CD133 KDR cells in patients with systemic sclerosis. Clin Exp Rheumatol 28 (5 Suppl 62):S19-S25.
334. Molins B, Peña E, Padro T, Casani L, Mendieta C, and Badimon L (2010) Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin. Arterioscler Thromb Vasc Biol 30:1246-1252.
335. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, Stern Y, and Mayeux R (1999) Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282:254-260.
336. Muck W (1998) Rational assessment of the interaction profile of cerivastatin sup-ports its low propensity for drug interactions. Drugs 56 (Suppl 1):15-23.
337. Muck W, Park S, Jager W, Voith B, Wandel E, Galle PR, and Schwarting A (2001) The pharmacokinetics of cerivastatin in patients on chronic hemodialysis. Int J Clin Pharmacol Ther 39:192-198.
338. Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35:255-260.
339. Muck W, Unger S, Kawano K, and Ahr G (1998) Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 45:583-590.
340. Mukhtar RY, Reid J, and Reckless JP (2005) Pitavastatin Int J Clin Pract 59(2): 239-252.
341. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, and Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
342. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K, and Ishikawa C (1994) Prevention of 1,2-dimethylhydrazineinduced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carci-nogenesis 15:2045-2048.
343. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, and Aizawa R (1996) Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A re-ductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87:798-804.
344. Nash DT and Fillit H (2006) Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol 97:1262-1265.
345. Nezasa K, Higaki K, Takeuchi M, Nakano M, and Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobi-otica 33:379-388.
346. Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacog-enomics 8:787-802.
347. Niemi M, Backman JT, Neuvonen M, and Neuvonen PJ (2003) Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br J Clin Pharmacol 56:427-432.
348. Niemi M, Neuvonen PJ, and Kivisto KT (2001) The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 70:58-65.
349. Nishida S, Matsuoka H, Tsubaki M, Tanimori Y, Yanae M, Fujii Y, and Iwaki M (2005) Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol Cell Biochem 269:109-114.
350. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, and Kao PN (2003) Simvastatin rescues rats from fatal pulmonary hyperten-sion by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645.
351. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071-1080.
352. Notarbartolo A, Davì G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, and Patrono C (1995) Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:247-251.
353. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, and Nissinen A (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17:14-20.
354. Nubel T, Dippold W, Kleinert H, Kaina B, and Fritz G (2004) Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 18:140-142.
355. Nyan M, Miyahara T, Noritake K, Hao J, Rodriguez R, Kuroda S, and Kasugai S (2010) Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate. J Biomed Mater Res B Appl Biomater 93:65-73.
356. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, and Takayanagi R (2001) Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 287:337-342.
357. Opper C, Clement C, Schwarz H, Krappe J, Steinmetz A, Schneider J, and Wese-mann W (1995) Increased number of high sensitive platelets in hypercholesterol-emia, cardiovascular diseases, and after incubation with cholesterol. Atheroscle-rosis 113:211-217.
358. Ostrowski SM, Wilkinson BL, Golde TE, and Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282:26832-26844.
359. Owens GK, Kumar MS, and Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767-801.
360. Pan HY, DeVault AR, Brescia D, Willard DA, McGovern ME, Whigan DB, and Ivashkiv E (1993a) Effect of food on pravastatin pharmacokinetics and pharma-codynamics. Int J Clin Pharmacol Ther Toxicol 31:291-294.
361. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, and Sugerman AA (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128-1135.
362. Pan HY, Waclawski AP, Funke PT, and Whigan D (1993b) Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 27:1029-1033.
363. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, and Galper JB (2002) 3-hy-droxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91:143-150.
364. Park JB, Zhang H, Lin CY, Chung CP, Byun Y, Park YS, and Yang VC (2011) Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors. J Surg Res http://dx.doi.org/10.1016/j.jss.2010.12.029.
365. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, and Shin JG (2008) Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38:1240-1251.
366. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC, and Geelong Osteoporosis Study (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540.
367. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40:567-572.
368. Patti G, Chello M, Gatto L, Alfano G, Miglionico M, Covino E, Di Sciascio G (2010) Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Cardiovasc Med (Hagerstown) 11:795-800.
369. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, et al. (2005) High-dose atorva-statin vs usual-dose simvastatin for secondary prevention after myocardial infarc-tion: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445.
370. Pedersen TR and Kjekshus J (2000) Statin drugs and the risk of fracture. JAMA 284:1921-1922.
371. Pendyala L, Yin X, Li J, Shinke T, Xu Y, Chen JP, King SB 3rd, Colley K, Goodchild T, Chronos N, et al. (2010) Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries. EuroIntervention 6:126-133.
372. Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y, Smrtka J, Vollmer T, Singh I, and Markovic-Plese S (2006) Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol 178:130-1399.
373. Pereira-Leal JB, Hume AN, and Seabra MC (2001) Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett 498:197-200.
374. Pérez-Castrillón JL, Abad L, Vega G, Sanz-Cantalapiedra A, García-Porrero M, Pinacho F, and Duen ̃ as A (2008) Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur Rev Med Pharmacol Sci, 12:83-88.
375. Pérez-Guerrero C, Márquez-Martín A, Herrera MD, Marhuenda E, and Alvarez de Sotomayor M (2005) Regulation of vascular tone from spontaneously hypertensive rats by the HMG-CoA reductase inhibitor, simvastatin. Pharmacology 74:209-215.
376. Peverill RE, Smolich JJ, Malan E, Goldstat R, and Davis SR (2006) Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas 53:158-165.
377. Phipps RP and Blumberg N (2009) Statin islands and PPAR ligands in platelets. Arterioscler Thromb Vasc Biol 29:620-621.
378. Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, de Bem AF, Prediger RD, and Tasca CI (2010) Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-(1-40) admin-istration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226:274-284.
379. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, and Violi F (2007) Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 5:1170-1178.
380. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, and McCormick LS (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341: 70-6.
381. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, and Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192.
382. Prasad KS, Andre P, He M, Bao M, Manganello J, and Phillips DR (2003) Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 100:12367-12371.
383. Preusch MR, Vanakaris A, Bea F, Ieronimakis N, Shimizu T, Konstandin M, Morris-Rosenfeld S, Albrecht C, Kranzhofer A, Katus HA, et al. (2010) Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur J Med Res 15:461-467.
384. Prueksaritanont T, Ma B, and Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56:120-124.
385. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisen-handler R, and Carlini EJ (2005) Comparative effects of fibrates on drug metab-olizing enzymes in human hepatocytes. Pharmacol Res 22:71-78.
386. Puccetti L, Bruni F, Bova G, Cercignani M, Pompella G, Auteri A, and Pasqui AL (2000) Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int J Clin Lab Res 30:147-156.
387. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, and Bruni F (2002) Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 32:901-908.
388. Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A, and Bruni F (2005) Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholester-olaemic patients. Eur J Clin Invest 35:47-51.
389. Quérin S, Lambert R, Cusson JR, Grégoire S, Vickers S, Stubbs RJ, Sweany AE, and Larochelle P (1991) Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 50:437-441.
390. Quion JA and Jones PH (1994) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 27:94-103.
391. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, and Soma M (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322:893-898.
392. Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, and Whitfield LR (1995) Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 35:990-994.
393. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, and Doggen CJ (2009) HMG-CoA-reductase inhibitors, other lipid lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Hae-most 7:514-520.
394. Rao S, Lowe M, Herliczek TW, and Keyomarsi K (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393-2402.
395. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, and Rao CV (2006) Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66:4542-4546.
396. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sam-bamurti K, Duff K, and Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321-331.
397. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, and Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509-512.
398. Resnick HE, Harris MI, Brock DB, and Harris TB (2000) American Diabetes Asso-ciation diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Sur-vey. Diabetes Care 23:176-180.
399. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207.
400. Ridley AJ (2001) Rho family proteins: coordinating cell responses. Trends Cell Biol 11:471-477.
401. Rikitake Y and Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97:1232-1235.
402. Robison RL, Suter W, and Cox RH (1994) Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. Fundam Appl Toxicol 23:9-20.
403. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, and McDowell I (2002) Use of lipid-lowering agents, indication bias, and the riskof dementia in community-dwelling elderly people. Arch Neurol 59:223-227.
404. Rossi J, Jonak P, Rouleau L, Danielczak L, Tardif JC, and Leask RL (2011) Differential response of endothelial cells to simvastatin when conditioned with steady, non-reversing pulsatile or oscillating shear stress. Ann Biomed Eng 39:402-413.
405. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, and Gensini GF (2010) Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis 9:80.
406. Roudier E, Mistafa O, and Stenius U (2006) Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 5:2706-2715.
407. Rozados VR, Hinrichsen LI, Binda MM, Gervasoni SI, Matar P, Bonfil RD, and Scharovsky OG (2008) Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models. Oncol Rep 19:1205-1211.
408. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, et al. (2009) Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72:1989-1993.
409. Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, et al. (2010) Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 33: 1954-1956.
410. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
411. Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, and Bender JR (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71:1262-1268.
412. Safaei H, Janghorbani M, Aminorroaya A, and Amini M (2007) Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol, 44:76-82.
413. Saito A, Saito N, Mol W, Furukawa H, Tsutsumida A, Oyama A, Sekido M, Sasaki S, and Yamamoto Y (2008) Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res 18:85-94.
414. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, and Hasegawa R (2005) Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 28:677-694.
415. Saito Y (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 5:921-936.
416. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, and Violi F (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111:412-419.
417. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, and Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524-4532.
418. Sassano A, Lo Iacono M, Antico G, Jordan A, Uddin S, Calogero RA, and Platanias LC (2009) Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 8:615-625.
419. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, Hirata Y, and Nagai R (2004) Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214-1220.
420. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125.
421. Schaefer CA, Kuhlmann CR, Gast C, Weiterer S, Li F, Most AK, Neumann T, Backenkohler U, Tillmanns H, Waldecker B, et al. (2004) Statins prevent oxidized low-density lipoprotein-and lysophosphatidylcholine-induced proliferation of hu-man endothelial cells. Vascul Pharmacol 41:67-73.
422. Schafer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, and Bauersachs J (2005) Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 25:1071-1077.
423. Schafer A, Fraccarollo D, Vogt C, Flierl U, Hemberger M, Tas P, Ertl G, and Bauersachs J (2007) Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with strepto-zotocin-induced diabetes mellitus. Biochem Pharmacol 73:1367-1375.
424. Schmidt-Lucke C, Fichtlscherer S, Rossig L, Kamper U, and Dimmeler S (2010) Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 211:249-254.
425. Schwindinger WF and Robishaw JD (2001) Heterotrimeric G-protein-dimers in growth and differentiation. Oncogene 20:1653-1660.
426. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, and Gaziano JM (2005) Statin use and fracture risk: study of a US veterans population. Arch Intern Med 165:2007-2012.
427. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, et al. (2003) Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41:275-279.
428. Sena A, Pedrosa R, and Graça Morais M (2003) Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 250:754-755.
429. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay JF, and Hennekens CH (2006) Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97:1332-1336.
430. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, and Farris PE (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162:318-325.
431. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, And PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630.
432. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307.
433. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of ceriv-astatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
434. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between ceriv-astatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
435. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and meta-bolic enzyme functions. Pharmacol Ther 112:71-105.
436. Siddals KW, Marshman E, Westwood M, and Gibson JM (2004) Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 279:38353-38359.
437. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, and Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464.
438. Sirtori CR (1993) Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther 60:431-459.
439. Sivaprasad U, Abbas T, and Dutta A (2006) Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5:2310-2316.
440. Smeeth L, Douglas I, Hall AJ, Hubbard R, and Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67:99-109.
441. Smit JW, Wijnne HJ, Schobben F, Sitsen A, De Bruin TW, and Erkelens DW (1995) Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Intern Med 122:678-680.
442. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, and Robinson WT (1993) Phar-macokinetics of fluvastatin and specific drug interactions. Am J Hypertens 6:375S-382S.
443. Soma MR, Corsini A, and Paoletti R (1992) Cholesterol and mevalonic acid modula-tion in cell metabolism and multiplication. Toxicol Lett 64-65:1-15.
444. Sørensen HT, Horvath-Puho E, Søgaard KK, Christensen S, Johnsen SP, Thomsen RW, Prandoni P, and Baron JA (2009) Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 7:521-528.
445. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, and Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94.
446. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, and Dimmeler S (2004) Statins enhance migratory capacity by upregu-lation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110:3136-3142.
447. Stanislaus R, Singh AK, and Singh I (2001) Lovastatin treatment decreases mono-nuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162.
448. Stein EA, Farnier M, Waldstreicher J, Mercuri M, And Simvastatin/Atorvastatin Study Group (2001) Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11:84-87.
449. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, and Banker DE (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 27:133-145.
450. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, and 4S Group (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777.
451. Sugatani J, Sadamitsu S, Kurosawa M, Ikushiro S, Sakaki T, Ikari A, and Miwa M (2010) Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats. Drug Metab Dispos 38:1655-1664.
452. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, and Oikawa S (2000) Compac-tin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688-692.
453. Sukhija R, Bursac Z, Kakar P, Fink L, Fort C, Satwani S, Aronow WS, Bansal D, and Mehta JL (2008) Effect of statins on the development of renal dysfunction. Am J Cardiol 101:975-979.
454. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, and Mehta JL (2009) Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 57:495-499.
455. Suzuki H, Inoue T, Watanabe Y, Kikuta T, Sato T, and Tsuda M (2010) Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipide-mia in peritoneal dialysis patients. Adv Perit Dial 26:53-57.
456. Swamy MV, Cooma I, Reddy BS, and Rao CV (2002) Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 20:753-759.
457. Tailor A, Lefer DJ, and Granger DN (2004) HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 286:H1402-H1407.
458. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, and Asahara T (1999) Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438.
459. Takai Y, Sasaki T, and Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208.
460. Takamiya Y, Miura S, Kawamura A, Tanigawa H, Zhang B, Iwata A, Nishikawa H, Matsuo K, Shirai K, and Saku K (2009) Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease. Coron Artery Dis 20:288-294.
461. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, and Kume H (2006) Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 35:722-729.
462. Takemoto M and Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719.
463. Tanaka Y, Nakayamada S, and Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4:325-328.
464. Tang QO, Tran GT, Gamie Z, Graham S, Tsialogiannis E, Tsiridis E, Linder T, and Tsiridis E (2008) Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 17:1435-1463.
465. Tatsuta M, Iishi H, Baba M, Iseki K, Yano H, Uehara H, Yamamoto R, and Nakai-zumi A (1998) Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 77:581-587.
466. Taylor JS, Reid TS, Terry KL, Casey PJ, and Beese LS (2003) Structure of mamma-lian protein geranylgeranyltransferase type-I. EMBO J 22:5963-5974.
467. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallén NH, and Jorneskog G (2010) Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 126:e225-31.
468. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, and Montague TJ (2000) Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 102: 1748-1754.
469. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491.
470. Thompson PD, Moyna NM, White CM, Weber KM, Giri S, and Waters DD (2002) The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis 161:301-306.
471. Tiessen RG, Lagerwey HJ, Jager GJ, and Sprenger HG (2010) [Drug interaction caused by communication problems. Rhabdomyolysis due to a combination of itraconazole and simvastatin]. Ned Tijdschr Geneeskd 154:A762.
472. Tikiz C, Unlu Z, Tikiz H, Ay K, Angin A, Onur E, Var A, and Tuzun C (2004) The effect of simvastatin on serum cytokine levels and bone metabolism in postmeno-pausal subjects: negative correlation between TNF-alpha and anabolic bone pa-rameters. J Bone Miner Metab 22:365-371.
473. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, et al. (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171-178.
474. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, and Hamel E (2009) Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 35:406-414.
475. Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, et al. (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 78:167-176.
476. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, and Demopou- los CA (2011) In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology 62:209-218.
477. Tschoepe D, Driesch E, Schwippert B, and Lampeter EF (1997) Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia 40:573-577.
478. Tse FL, Jaffe JM, and Troendle A (1992) Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630-638.
479. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, and Mjorndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and sim-vastatin acid. Eur J Clin Pharmacol 59:879-882.
480. Umemura T and Higashi Y (2008) Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci 108:1-6.
481. Undas A, Brummel-Ziedins KE, and Mann KG (2005) Statins and blood coagulation. Arterioscler Thromb Vasc Biol 25:287-294.
482. Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M, Hofmann WK, de Vos S, Zeiher AM, and Dimmeler S (2005) FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial pro-genitor cells. FASEB J 19:974-976.
483. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A, and Ito S (2008) Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertens Res 31:2085-2096.
484. Uysal AR, Delibasi T, Erdogan MF, Kamel N, Baskal N, Tonyukuk V, Corapcioglu D, Gullu S, and Erdogan G (2007) Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract 13:114-116.
485. Uzzan B, Cohen R, Nicolas P, Cucherat M, and Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40:1581-1587.
486. van Luin M, Colbers A, Van Ewijk-Beneken Kolmer EW, Verweij-van Wissen CP, Schouwenberg B, Hoitsma A, da Silva HG, and Burger DM (2010) Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr 55:82-86.
487. van Staa TP, Wegman S, de Vries F, Leufkens B, and Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855.
488. Vaquero MP, Sánchez Muniz FJ, Jiménez Redondo S, Prats Oliván P, Higueras FJ, and Bastida S (2010) Major diet-drug interactions affecting the kinetic character-istics and hypolipidaemic properties of statins. Nutr Hosp 25:193-206.
489. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, and Schonbeck U (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049-1052.
490. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, and Dimmeler S (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89:E1-E7.
491. Vaughan CJ (2003) Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 91:23B-29B.
492. Verzini F, De Rango P, Parlani G, Giordano G, Caso V, Cieri E, Isernia G, and Cao P (2011) Effects of statins on early and late results of carotid stenting. J Vasc Surg 53:71-79.
493. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, Soria J, and Hong L (2002) Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22:623-629.
494. Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, Duranti E, Daghini E, Giannarelli C, Blandizzi C, et al. (2009) Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 53:1008-1016.
495. Vitols S, Angelin B, and Juliusson G (1997) Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans-in vitro and in vivo stud-ies. Lipids 32:255-262.
496. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, and Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608.
497. Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, and Aukrust P (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in pa-tients with coronary artery disease. J Am Coll Cardiol 41:1460-1467.
498. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, and Isner JM (2002) Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incor-poration of bone marrow-derived endothelial progenitor cells. Circulation 105: 3017-3024.
499. Walter T, Szabo S, Suselbeck T, Borggrefe M, Lang S, Swoboda S, Hoffmeister HM, and Dempfle CE (2010) Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. Clin Drug Investig 30:453-460.
500. Wang CY, Zhong WB, Chang TC, Lai SM, and Tsai YF (2003) Lovastatin, a 3-hy-droxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026.
501. Wang E, Casciano CN, Clement RP, and Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 18:800-806.
502. Wang HR, Li JJ, Huang CX, and Jiang H (2005) Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353:53-60.
503. Wang IK, Lin-Shiau SY, and Lin JK (2000a) Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 86:83-91.
504. Wang IK, Lin-Shiau SY, and Lin JK (2000b) Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 59:245-254.
505. Wang J, Xiao Y, Luo M, Zhang X, and Luo H (2010a) Statins for multiple sclerosis. Cochrane Database Syst Rev 12:CD008386.
506. Wang L, Gong F, Dong X, Zhou W, and Zeng Q (2010b) Regulation of vascular smooth muscle cell proliferation by nuclear orphan receptor Nur77. Mol Cell Biochem 341:159-166.
507. Wang PS, Solomon DH, Mogun H, and Avorn J (2000c) HMG-CoA reductase inhib-itors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216.
508. Wang Y, Chang H, Zou J, Jin X, and Qi Z (2011) The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray. Biomed Pharmacother 65:118-122.
509. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, and German Diabetes and Dialysis Study Investigators (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248.
510. Watala C, Boncler M, and Gresner P (2007) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57:42-58.
511. Weis M, Heeschen C, Glassford AJ, and Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105:739-745.
512. Weitz-Schmidt G (2003) Lymphocyte function-associated antigen-1 blockade by st-atins: molecular basis and biological relevance. Endothelium 10:43-47.
513. Welzenbach K, Hommel U, and Weitz-Schmidt G (2002) Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lympho-cyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 277:10590-10598.
514. Werner M, Sacher J, and Hohenegger M (2004) Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdo-myosarcoma cells. Br J Pharmacol 143:715-724.
515. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, and Nickenig G (2002) Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 22:1567-1572.
516. Williams D and Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370.
517. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr., Napoli C, Ritman EL, and Lerman A (2002) Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105:415-418.
518. Winter-Vann AM and Casey PJ (2005) Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 5:405-412.
519. Wolozin B, Kellman W, Ruosseau P, Celesia GG, and Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coen-zyme A reductase inhibitors. Arch Neurol 57:1439-1443.
520. Wu X, Lin D, Li G, and Zuo Z (2010) Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells. Eur J Pharmacol 636:114-120.
521. Xiao H, Zhang Q, Lin Y, Reddy BS, and Yang CS (2008) Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122:2115-2124.
522. Yaffe K, Barrett-Connor E, Lin F, and Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59:378-384.
523. Yamamoto A, Hoshi K, and Ichihara K (1998) Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxi-dation in rat liver microsomes. Eur J Pharmacol 361:143-149.
524. Yang CC, Jick SS, and Jick H (2002) Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 53:101-105.
525. Yang L, Gao YJ, and Lee RM (2005) The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur J Pharmacol 518:145-151.
526. Yang Z, Xiao H, Jin H, Koo PT, Tsang DJ, and Yang CS (2010) Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer 126:852-863.
527. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, et al. (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23:295-299.
528. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, et al. (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Athero-sclerosis 172:85-93.
529. Yokoyama K, Goodwin GW, Ghomashchi F, Glomset J, and Gelb MH (1992) Protein prenyltransferases. Biochem Soc Trans 20:489-494.
530. Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, Okumura K, and Murohara T (2010) Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J 74:195-202.
531. Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, Sugiura T, and Iwasaka T (2009) Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insuffi-ciency. J Cardiol 54:192-198.
532. Young SG, Meta M, Yang SH, and Fong LG (2006) Prelamin A farnesylation and progeroid syndromes. J Biol Chem 281:39741-39745.
533. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84.
534. Yue J, Zhang X, Dong B, and Yang M (2010) Statins and bone health in postmeno-pausal women: a systematic review of randomized controlled trials. Menopause 17:1071-1079.
535. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC, and Cache County Study investigators (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62:217-224.
536. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, and Negrin RS (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 110:4588-4598.
537. Zerial M and McBride H (2001) Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2:107-117.
538. Zhang FL and Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269.
539. Zhang S, Rahman M, Zhang S, Qi Z, and Thorlacius H (2011) Simvastatin antago-nizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. J Leukoc Biol 89:735-742.
540. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, et al. (2007) Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 13:5480-5487.
541. Zhong WB, Liang YC, Wang CY, Chang TC, and Lee WS (2005) Lovastatin sup-presses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho gera-nylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12:615-629.
542. Zhou Q and Liao JK (2010) Pleiotropic effects of statins.-Basic research and clinical perspectives-. Circ J 74:818-826.
543. Zhu H, Liang Z, and Li G (2009) Rabex-5 is a Rab22 effector and mediates a Rab22-Rab5 signaling cascade in endocytosis. Mol Biol Cell 20:4720-4729.